38 related articles for article (PubMed ID: 33377576)
21. Evaluation of STAT3 decoy oligodeoxynucleotides' synergistic effects on radiation and/or chemotherapy in metastatic breast cancer cell line.
Johari B; Rahmati M; Nasehi L; Mortazavi Y; Faghfoori MH; Rezaeejam H
Cell Biol Int; 2020 Dec; 44(12):2499-2511. PubMed ID: 32841450
[TBL] [Abstract][Full Text] [Related]
22. Increasing the colon cancer cells sensitivity toward radiation therapy via application of Oct4-Sox2 complex decoy oligodeoxynucleotides.
Johari B; Rezaeejam H; Moradi M; Taghipour Z; Saltanatpour Z; Mortazavi Y; Nasehi L
Mol Biol Rep; 2020 Sep; 47(9):6793-6805. PubMed ID: 32865703
[TBL] [Abstract][Full Text] [Related]
23. Suppressing the metastatic properties of the breast cancer cells using STAT3 decoy oligodeoxynucleotides: A promising approach for eradication of cancer cells by differentiation therapy.
Rahmati M; Johari B; Kadivar M; Rismani E; Mortazavi Y
J Cell Physiol; 2020 Jun; 235(6):5429-5444. PubMed ID: 31912904
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo.
Zhang X; Liu P; Zhang B; Mao H; Shen L; Ma Y
Int J Mol Med; 2013 Sep; 32(3):623-8. PubMed ID: 23828376
[TBL] [Abstract][Full Text] [Related]
25. Role of Oct4-Sox2 complex decoy oligodeoxynucleotides strategy on reverse epithelial to mesenchymal transition (EMT) induction in HT29-ShE encompassing enriched cancer stem-like cells.
Bigdelou Z; Mortazavi Y; Saltanatpour Z; Asadi Z; Kadivar M; Johari B
Mol Biol Rep; 2020 Mar; 47(3):1859-1869. PubMed ID: 32016633
[TBL] [Abstract][Full Text] [Related]
26. Application of decoy oligodeoxynucleotides strategy for inhibition of cell growth and reduction of metastatic properties in nonresistant and erlotinib-resistant SW480 cell line.
Asadi Z; Fathi M; Rismani E; Bigdelou Z; Johari B
Cell Biol Int; 2021 May; 45(5):1001-1014. PubMed ID: 33377576
[TBL] [Abstract][Full Text] [Related]
27. Targeting STAT3 in Cancer with Nucleotide Therapeutics.
Lau YK; Ramaiyer M; Johnson DE; Grandis JR
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31671769
[TBL] [Abstract][Full Text] [Related]
28. Oligonucleotide-Based Therapeutics for STAT3 Targeting in Cancer-Drug Carriers Matter.
Molenda S; Sikorska A; Florczak A; Lorenc P; Dams-Kozlowska H
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067351
[TBL] [Abstract][Full Text] [Related]
29. Decoys as potential therapeutic tools for diabetes.
Mahjoubin-Tehran M; Rezaei S; Atkin SL; Montecucco F; Sahebkar A
Drug Discov Today; 2021 Jul; 26(7):1669-1679. PubMed ID: 33862194
[TBL] [Abstract][Full Text] [Related]
30.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
31.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
